advertisement
Pharmaceuticals (Basel, Switzerland) 8
Showing records 1 to 8 | Display all abstracts in Pharmaceuticals (Basel, Switzerland)96254 Non-Pigmented Ciliary Epithelium-Derived Extracellular Vesicles Loaded with SMAD7 siRNA Attenuate Wnt Signaling in Trabecular Meshwork Cells In Vitro
Tabak S
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96063 In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy
Li H
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96254 Non-Pigmented Ciliary Epithelium-Derived Extracellular Vesicles Loaded with SMAD7 siRNA Attenuate Wnt Signaling in Trabecular Meshwork Cells In Vitro
Tabak S; Tabak S; Feinshtein V
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96063 In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy
Ibrahim MM
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96254 Non-Pigmented Ciliary Epithelium-Derived Extracellular Vesicles Loaded with SMAD7 siRNA Attenuate Wnt Signaling in Trabecular Meshwork Cells In Vitro
Schreiber-Avissar S
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96063 In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy
Chen H
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96254 Non-Pigmented Ciliary Epithelium-Derived Extracellular Vesicles Loaded with SMAD7 siRNA Attenuate Wnt Signaling in Trabecular Meshwork Cells In Vitro
Beit-Yannai E
Pharmaceuticals (Basel, Switzerland) 2021; 14:
96063 In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy
Li W; Jablonski MM
Pharmaceuticals (Basel, Switzerland) 2021; 14:
